Dr Yong Du
MBBS MSc PhD FRCP Nuclear Medicine Physician
Languages spoken
English
Expert in
Lymphoma, Neuroendocrine tumours, Prostate cancer
Overview
Special clinical interest in PET/CT, SPECT/CT, Radionuclide Target Therapy
Dr Yong Du is a Consultant Physician in Nuclear Medicine & PET/CT. He is the Clinical Director of Nuclear Medicine & Theranostics of GenesisCare UK.
He completed Nuclear Medicine specialist training at the Institute of Nuclear Medicine in UCLH and obtained his PhD degree in radioummunotherapy for lymphoma.
Dr Yong Du leads the radionuclide therapy services at the Royal Marsden Hospital, the biggest cancer centre in the UK, he’s also in the NHS England advisory group for radionuclide targeted therapy, and British Nuclear Medicine Society and Royal College of Physicians representative to NICE on Clinical Nuclear Medicine.
Dr Yong Du has extensive experience in both PET/CT imaging and Radionuclide Targeted Therapy, he’s published first-authored research articles in high impact oncology journals including the Journal of Clinical Oncology, Blood, Cancer Research.
He was the first recipient of the UK HEFCE Clinical Senior Lectureship Award in the Nuclear Medicine specialty.
Dr Yong Du and Mr Philip Charlesworth explain what Theranostics and 177Lutetium PSMA therapy is and how it works for patients with advanced prostate cancer.
Dr Yong Du pioneered Lu-177-PSMA treatment for prostate cancer patients in the United Kingdom and was awarded the first clinical ARSAC licence to treat in February 2018. Using this novel technology, he has treated over 200 patients, he has also treated a large number of patients using other radionuclides including I-131 for thyrotoxicosis and thyroid cancer, Zevalin for lymphoma, MIBG for neuroblastoma, Radium-223 (Xofigo) for prostate cancer, and PRRT for neuroendocrine tumour.
Hear from Steve, Dr Yong Du’s patient who received Lu-177-PSMA treatment for prostate cancer
Career positions
- Consultant Physician in Nuclear Medicine & PET/CT
- Clinical Lead for radionuclide therapy services at the Royal Marsden Hospital
Education
- Institute of Nuclear Medicine in UCLH
Expertise and interests
- Nuclear Medicine
- PET/CT
- SPECT/CT
- Radionuclide Target Therapy
Professional associations
- GMC
- MPS
- RCP
- BNMS
- EANM
- Dr Yong Du served as a Trustee of the British Nuclear Medicine Society and is a committee member of a number of national and international professional bodies including NCRI CTRad and Radionuclide Target Therapy Committee of BNMS.
Awards
- HEFCE Clinical Senior lecturer (Awarded in June 2009)
Publications & affiliations
- He has led a number of national and international research projects and has published first-authored research articles in high impact oncology journals including the Journal of Clinical Oncology, Blood, Cancer Research, EJNMMI, etc.